Columns The MS Wire - A Column by Ed Tobias Pregnancy, DMTs, and MS: A New Study Pregnancy, DMTs, and MS: A New Study by Ed Tobias | December 14, 2018 Share this article: Share article via email Copy article link Many years ago a woman I know who has multiple sclerosis (MS) became pregnant. After her child was born her MS became significantly worse. There have been many studies on the impact of pregnancy on someone with MS, with most concluding that the number of MS relapses are reduced during pregnancy but tend to increase immediately following birth, particularly in the first three months. There are other alternative opinions; I found one on the Johns Hopkins Medicine website. It advises that: “Fortunately, pregnancy does not appear to speed up the course or worsen the effects of MS.” I’m not so sure that’s correct. Factors affecting MS and pregnancy A recent study looks at what may affect the course of MS for a woman who becomes pregnant. The study, by a group of Austrian researchers, followed 239 women with relapsing-remitting MS (RRMS) through 387 pregnancies. It compared their relapse rates and their Expanded Disability Status Scale (EDSS) scores before, during, and after pregnancy. The study concluded that four factors can affect the risk of a relapse and disability progression after a woman conceives: Her relapse activity before conception, her EDSS score at conception, use of a highly effective disease-modifying therapy (H-DMT) before conception, and length of the DMT washout period. In addition, two factors had an impact on relapses and progression after the birth: Relapse activity before and during the pregnancy and the use of a H-DMT pre-conception. In this case the DMT was Tysabri (natalizumab). Importantly, researchers found that an early restart of the DMT reduced the risk of postpartum relapse. Recommendations Based upon their research, the Austrian investigators believe that a one-size-fits-all approach isn’t appropriate when dealing with MS and pregnancy. Rather, they recommend: “A personalized approach in planning pregnancy in women with MS while on H-DMT needs to be adopted. It seems reasonable maintaining natalizumab closer to conception and restarting the drug early postpartum to reduce the considerable risk of disease reactivation during early pregnancy and after delivery.” Currently, there is limited guidance on how long of a washout of a DMT is necessary before conception and how soon after delivery a DMT can be resumed safely. So, a woman’s neurologist, hopefully in consultation with her obstetrician, should be her guide in this situation. I think it also couldn’t hurt to get more than one opinion, but be prepared for them to be different. Let’s also advocate for more studies of the MS-pregnancy equation, to help determine what will create the best outcome for both mother and child. You’re invited to follow my personal blog at www.themswire.com. *** Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. He’s also the author of “The Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.” Ed and his wife split their time between the Washington, D.C. suburbs and Florida’s Gulf Coast, trying to follow the sun. Tags disease-modifying therapies (DMTs), DMTs, MS and pregnancy, Tysabri (natalizumab) Comments Greg tully Great help I feel I have more energy sleep better. My joints are not sore I find overall I feel better also I get asked for my bottle when I have finished my months allowance Reply Ed Tobias Greg, Is your comment intended to respond to my column about pregnancy and MS? I suspect you were responding to a different post. Ed Reply Sarah Why are they not looking into the fact that some MS relapse triggers could be hormonal? Hence why more women than men get MS? Reply Zuzana Ifrim Sarah....this is just what I am saying too! Reply Shammalammadingdong Until these studies start to take into account lifestyle factors, especially diet, a large amount of variability will he unaccounted for Reply ita Sara I had 5 children born between 1976 and 1985. Had no clue my younger daughter would be dx'd with MS at age 20 and myself in 2005 at age 57. I had no clues til then. I did have ms hugs but neither myself nor my internist new what they were and thought it was a muscle contraction. My daughter had TM and then ON and then I had TM my first symptoms which I knew right away what it was and that lead to my own dx of MS. My lesions then and now were inactive. My daughter as well is doing well and her doc. took her off MS meds. I too have not progressed. So in my case was it the pregnancies? Was it being on HRT (and still am) that was a factor? Or is it that MS has different entities that do not get worse? So much more to learn when it affects people so differently. Was there a final decision on the estriol study as to whether that + Copaxone was helpful in MS? Reply Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
April 30, 2024 News by Andrea Lobo, PhD Committee favors approval of under-the-skin Ocrevus in Europe